Giandomenico Russo

List of Publications by Year
in descending order

96 papers	7,313 citations	87843 38 h-index	62565 80 g-index
97 all docs	97 docs citations	97 times ranked	12055 citing authors

#	Article	IF	Citations
1	Genomic Classification of Cutaneous Melanoma. Cell, 2015, 161, 1681-1696.	13.5	2,562
2	Human chronic lymphocytic leukemia modeled in mouse by targeted TCL1 expression. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 6955-6960.	3.3	557
3	Identification of the TCL1 gene involved in T-cell malignancies.. Proceedings of the National Academy of Sciences of the United States of America, 1994, 91, 12530-12534.	3.3	257
4	Cytokine and chemokine levels in systemic sclerosis: relationship with cutaneous and internal organ involvement. Clinical and Experimental Immunology, 2004, 138, 540-546.	1.1	214
5	Low frequency of alterations of the Î± (PPP2R1A) and Î² (PPP2R1B) isoforms of the subunit A of the serine-threonine phosphatase 2A in human neoplasms. Oncogene, 2000, 19, 1191-1195.	2.6	206
6	Tcl1 enhances Akt kinase activity and mediates its nuclear translocation. Proceedings of the National Academy of Sciences of the United States of America, 2000, 97, 3028-33.	3.3	168
7	Human TCR-gamma+/delta+, CD8+ T lymphocytes recognize tetanus toxoid in an MHC-restricted fashion.. Journal of Experimental Medicine, 1989, 169, 1847-1851.	4.2	167
8	Skin homing of Sèzary cells involves SDF-1-CXCR4 signaling and down-regulation of CD26/dipeptidylpeptidase IV. Blood, 2006, 107, 1108-1115.	0.6	148
9	Deregulated expression of TCL1 causes T cell leukemia in mice. Proceedings of the National Academy of Sciences of the United States of America, 1998, 95, 3885-3889.	3.3	146
10	Chronic lymphocytic leukemia and regulatory B cells share IL-10 competence and immunosuppressive function. Leukemia, 2013, 27, 170-182.	3.3	145
11	Familial Cancer Associated with a Polymorphism inARLTS1. New England Journal of Medicine, 2005, 352, 1667-1676.	13.9	119
12	MicroRNA profiling reveals that miR-21, miR486 and miR-214 are upregulated and involved in cell survival in SÃ©zary syndrome. Cell Death and Disease, 2011, 2, e151-e151.	2.7	119
13	Molecular analysis of a t(7;14)(g35;g32) chromosome translocation in a T cell leukemia of a patient with ataxia telangiectasia. Cell, 1988, 53, 137-144.	13.5	117
14	Loss of RALT/MIG-6 expression in ERBB2-amplified breast carcinomas enhances ErbB-2 oncogenic potency and favors resistance to Herceptin. Oncogene, 2005, 24, 4540-4548.	2.6	111
15	Abnormalities at 14q32.1 in T cell malignancies involve two oncogenes. Proceedings of the National Academy of Sciences of the United States of America, 1999, 96, 2949-2951.	3.3	109
16	Molecular analysis of a t(14;14) translocation in leukemic T-cells of an ataxia telangiectasia patient.. Proceedings of the National Academy of Sciences of the United States of America, 1989, 86, 602-606.	3.3	98
17	Cloning of the gene encoding the delta subunit of the human T-cell receptor reveals its physical organization within the alpha-subunit locus and its involvement in chromosome translocations in T-cell malignancy.. Proceedings of the National Academy of Sciences of the United States of America, 1988, 85, 3933-3937.	3.3	97
18	Hepatitis C Virus Drives the Unconstrained Monoclonal Expansion of VH1â€“69-Expressing Memory B Cells in Type II Cryoglobulinemia: A Model of Infection-Driven Lymphomagenesis. Journal of Immunology, 2005, 174, 6532-6539.	0.4	97

#	Article	IF	Citations
19	miR-24 triggers epidermal differentiation by controlling actin adhesion and cell migration. Journal of Cell Biology, 2012, 199, 347-363.	2.3	87
20	Quality of life and psychological distress in patients with cutaneous lymphoma. British Journal of Dermatology, 2009, 160, 815-822.	1.4	85
21	TCL1 participates in early embryonic development and is overexpressed in human seminomas. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 11712-11717.	3.3	82
22	Skewed T-cell receptor repertoire, decreased thymic output, and predominance of terminally differentiated T cells in ataxia telangiectasia. Blood, 2002, 100, 4082-4089.	0.6	82
23	Identification of new genes associated with breast cancer progression by gene expression analysis of predefined sets of neoplastic tissues. International Journal of Cancer, 2008, 123, 1327-1338.	2.3	79
24	Mechanism, Consequences, and Therapeutic Targeting of Abnormal IL15 Signaling in Cutaneous T-cell Lymphoma. Cancer Discovery, 2016, 6, 986-1005.	7.7	79
25	Chromosome walking on the TCL1 locus involved in T-cell neoplasia.. Proceedings of the National Academy of Sciences of the United States of America, 1993, 90, 9275-9279.	3.3	74
26	Identification of Key Regions and Genes Important in the Pathogenesis of SÃ©zary Syndrome by Combining Genomic and Expression Microarrays. Cancer Research, 2009, 69, 8438-8446.	0.4	68
27	Heterogeneity of immunological abnormalities in ataxia-telangiectasia. Journal of Clinical Immunology, 1983, 3, 135-141.	2.0	58
28	Biased T-cell receptor repertoires in patients with chromosome 22q11.2 deletion syndrome (DiGeorge) Tj ETQq0 0 0 rgBT /Overlock 10 T	1.1	56
29	Variant of ataxia-telangiectasia with low-level radiosensitivity. Human Genetics, 1985, 70, 274-7.	1.8	55
30	Molecular resemblance of an AIDS-associated lymphoma and endemic Burkitt lymphomas: implications for their pathogenesis.. Proceedings of the National Academy of Sciences of the United States of America, 1989, 86, 8907-8911.	3.3	53
31	microRNAome Expression in Chronic Lymphocytic Leukemia: Comparison with Normal B-cell Subsets and Correlations with Prognostic and Clinical Parameters. Clinical Cancer Research, 2014, 20, 4141-4153.	3.2	52
32	Skewed Expression of Activation, Differentiation and Homing-Related Antigens in Circulating Cells from Patients with Cutaneous T Cell Lymphoma Associated with CD7â€“ Tâ€‰Helper Lymphocytes Expansion. Journal of Investigative Dermatology, 1999, 113, 622-627.	0.3	47
33	Comprehensive analysis of PTEN status in SÃ©zary syndrome. Blood, 2013, 122, 3511-3520.	0.6	47
34	Identification of the TCL6 genes within the breakpoint cluster region on chromosome 14q32 in T-cell leukemia. Oncogene, 2000, 19, 2796-2802.	2.6	45
35	CXCL13 Is Highly Produced by Sèzary Cells and Enhances Their Migratory Ability via a Synergistic Mechanism Involving CCL19 and CCL21 Chemokines. Cancer Research, 2008, 68, 7137-7146.	0.4	45
36	Circulating CD8+ lymphocytes, white blood cells, and survival in patients with mycosis fungoides. British Journal of Dermatology, 2005, 153, 324-330.	1.4	44

#	Article	IF	Citations
37	Acquired Chromosome 11q Deletion Involving the Ataxia Teleangiectasia Locus in B-Cell Non-Hodgkinâ€™s Lymphoma: Correlation With Clinicobiologic Features. Journal of Clinical Oncology, 2000, 18, 2607-2614.	0.8	41
38	Clonal B cells of HCVâ€associated mixed cryoglobulinemia patients contain exhausted marginal zoneâ€like and CD21^{low} cells overexpressing Stra13. European Journal of Immunology, 2012, 42, 1468-1476.	1.6	40
39	TCL1 transgenic mouse model as a tool for the study of therapeutic targets and microenvironment in human B-cell chronic lymphocytic leukemia. Cell Death and Disease, 2016, 7, e2071-e2071.	2.7	40
40	Molecular Cloning and Characterization ofZNF202:A New Gene at 11q23.3 Encoding Testis-Specific Zinc Finger Proteins. Genomics, 1998, 52, 358-362.	1.3	34
41	Impaired T- and B-cell development in Tcl1-deficient mice. Blood, 2005, 105, 1288-1294.	0.6	33
42	T-cell receptor genes and ataxia telangiectasia. Nature, 1985, 313, 186-186.	13.7	32
43	The murine Tcl1 oncogene: embryonic and lymphoid cell expression. Oncogene, 1997, 15, 919-926.	2.6	32
44	Clonal expansion and functional exhaustion of monoclonal marginal zone B cells in mixed cryoglobulinemia: The yin and yang of HCV-driven lymphoproliferation and autoimmunity. Autoimmunity Reviews, 2013, 12, 430-435.	2.5	30
45	Activity of azelaic acid on cultures of lymphoma- and leukemia-derived cell lines, normal resting and stimulated lymphocytes and 3T3 fibroblasts. Biochemical Pharmacology, 1985, 34, 1653-1658.	2.0	29
46	miR-181b as a therapeutic agent for chronic lymphocytic leukemia in the Eμ-TCL1 mouse model. Oncotarget, 2015, 6, 19807-19818.	0.8	29
47	Blood and skin-derived Sezary cells: differences in proliferation-index, activation of PI3K/AKT/mTORC1 pathway and its prognostic relevance. Leukemia, 2019, 33, 1231-1242.	3.3	28
48	Exon-Scanning Mutation Analysis of the ATM Gene in Patients with Ataxia-T elangiectasia. European Journal of Human Genetics, 1996, 4, 352-355.	1.4	27
49	Primary cutaneous B-cell lymphoma is associated with somatically hypermutated immunoglobulin variable genes and frequent use of VH1-69 and VH4-59 segments. British Journal of Dermatology, 2010, 162, 611-618.	1.4	24
50	T Cell Receptor-Vβ2 Analysis Identifies a Dominant CD60+ CD26â€“ CD49dâ€“ T Cell Clone in the Peripheral Blood of SÃ©zary Syndrome Patients. Journal of Investigative Dermatology, 2002, 119, 193-196.	0.3	22
51	TCL1 promotes blastomere proliferation through nuclear transfer, but not direct phosphorylation, of AKT/PKB in early mouse embryos. Cell Death and Differentiation, 2008, 15, 420-422.	5.0	22
52	Proteomics plus genomics approaches in primary immunodeficiency: the case of immune dysregulation, polyendocrinopathy, enteropathy, X-linked (IPEX) syndrome. Clinical and Experimental Immunology, 2011, 167, 120-128.	1.1	22
53	Anti-leukemic activity of microRNA-26a in a chronic lymphocytic leukemia mouse model. Oncogene, 2017, 36, 6617-6626.	2.6	22
54	Persistently Biased T-Cell Receptor Repertoires in HIV-1-Infected Combination Antiretroviral Therapy???Treated Patients Despite Sustained Suppression of Viral Replication. Journal of Acquired Immune Deficiency Syndromes (1999), 2003, 34, 140-154.	0.9	21

#	Article	IF	Citations
55	Phenotypically immature IgG-bearing B cells in patients with hypogammaglobulinemia. Journal of Clinical Immunology, 1986, 6, 21-25.	2.0	19
56	Preclinical Evidence for Targeting PI3K/mTOR Signaling with Dual-Inhibitors as a Therapeutic Strategy against Cutaneous T-CellÂLymphoma. Journal of Investigative Dermatology, 2020, 140, 1045-1053.e6.	0.3	19
57	The role of 9-O-acetylated ganglioside D3 (CD60) and Â4Â1 (CD49d) expression in predicting the survival of patients with Sezary syndrome. Haematologica, 2010, 95, 1905-1912.	1.7	16
58	Isolation of a cDNA clone encoding a novel form of granzyme B from human NK cells and mapping to chromosome 14. Human Genetics, 1990, 84, 465-70.	1.8	15
59	Specific IgE toward Allergenic Molecules Is a New Prognostic Marker in Patients with SÃ©zary Syndrome. International Archives of Allergy and Immunology, 2012, 157, 159-167.	0.9	15
60	Compatible solutes from hyperthermophiles improve the quality of DNA microarrays. BMC Biotechnology, 2007, 7, 82.	1.7	14
61	Hypogammaglobulinemia with hyper-IgM, severe T-cell defect, and abnormal recirculation of OKT4 lymphocytes in a girl with chronic lymphadenopathy. Clinical Immunology and Immunopathology, 1986, 38, 256-264.	2.1	13
62	SÃ©zary Syndrome, recent biomarkers and new drugs. Chinese Clinical Oncology, 2019, 8, 2-2.	0.4	13
63	Molecular Genetics of Lymphoid Tumorigenesis. Progress in Molecular Biology and Translational Science, 1989, 36, 269-280.	1.9	12
64	Loss of the candidate tumor suppressor ZEB1 (TCF8, ZFHX1A) in SÃ©zary syndrome. Cell Death and Disease, 2018, 9, 1178.	2.7	10
65	a4b1+and a4b7+CD4+T cell numbers increase and CLA+CD4+T cell numbers decrease in systemic sclerosis. Clinical and Experimental Immunology, 2005, 139, 551-557.	1.1	8
66	The Tcl1 oncogene defines secondary hair germ cells differentiation at catagenâ€“telogen transition and affects stem-cell marker CD34 expression. Oncogene, 2009, 28, 1329-1338.	2.6	7
67	Protein kinase Akt2/PKBÎ² is involved in blastomere proliferation of preimplantation mouse embryos. Journal of Cellular Physiology, 2020, 235, 3393-3401.	2.0	7
68	Telomerase activity, apoptosis and cell cycle progression in ataxia telangiectasia lymphocytes expressing TCL1. British Journal of Cancer, 2003, 89, 1091-1095.	2.9	5
69	Single TCR-VÎ²2 evaluation discloses the circulating T cell clone in Sezary syndrome: one family fits all!. Archives of Dermatological Research, 2015, 307, 487-493.	1.1	5
70	T Cell Leukemia/Lymphoma 1A is essential for mouse epidermal keratinocytes proliferation promoted by insulin-like growth factor 1. PLoS ONE, 2018, 13, e0204775.	1.1	5
71	Reduction of T Lymphoma Cells and Immunological Invigoration in a Patient Concurrently Affected by Melanoma and Sezary Syndrome Treated With Nivolumab. Frontiers in Immunology, 2020, 11, 579894.	2.2	4
72	Genetically Driven CD39 Expression Affects Sezary Cell Viability and IL-2 Production and Detects Two Patient Subsets with Distinct Prognosis. Journal of Investigative Dermatology, 2022, 142, 3009-3019.e9.	0.3	4

#	Article	IF	Citations
73	The design of a specific ligand of HIV gp120. , 1997, 3, 383-390.		3
74	Expression of TCL1 and CD27 in primary cutaneous B-cell lymphomas. Histopathology, 2006, 49, 343-348.	1.6	3
75	IgE reactivity and survival probabilities in SÃ©zary syndrome. Journal of the American Academy of Dermatology, 2015, 72, e177.	0.6	3
76	Loss of Î²-arrestin-2 gene and possible functional consequences on Sezary Syndrome. Cell Cycle, 2019, 18, 1292-1294.	1.3	2
77	Pleomorphicskin eruptions in a COVIDâ€19 affected patient: Case report and review of the literature. Immunity, Inflammation and Disease, 2021, 9, 617-621.	1.3	2
78	Challenging Cutaneous T-Cell Lymphoma: What Animal Models Tell us So Far. Journal of Investigative Dermatology, 2022, , .	0.3	2
79	From single-cell signature to prognostic factors: the case of SÃ©zary syndrome. Expert Review of Clinical Immunology, 2012, 8, 699-701.	1.3	1
80	BCR/ABL1-positive acute lymphoblastic leukemia relapsing asBCR/ABL1-negative acute lymphoblastic leukemia. Leukemia and Lymphoma, 2013, 54, 2065-2067.	0.6	1
81	Abstract 474: Alterations of micro-RNAs are associated with melanoma resistance to BRAF inhibitors: Role of miR-126. , 2018, , .		1
82	Combined High-Throughput Approaches Reveal the Signals Driven by Skin and Blood Environments and Define the Tumor Heterogeneity in SÃ©zary Syndrome. Cancers, 2022, 14, 2847.	1.7	1
83	The molecular genetics of chromosomal translocations in lymphoid malignancy. Advances in Genome Biology, 1995, 3, 211-231.	0.3	0
84	The B-Cell Chemoattractant Factor CXCL13 Is Expressed in the Malignant Lymphocyte of the Sezary Syndrome.. Blood, 2006, 108, 2292-2292.	0.6	0
85	Genomic Tumour Profiling with High-Density Oligonucleotide SNP Array in Sèzary Syndrome.. Blood, 2006, 108, 2289-2289.	0.6	0
86	Abstract 1736: Skewed usage of TCRVbeta repertoire and predictive role of CD60 and CD49d expression in the survival rate of patients with SÃ©zÃry Syndrome. , 2010, , .		0
87	TCL1. , 2011, , 3625-3629.		0
88	Abstract 150: Regulation of TGFB receptor by miR21 in Sezary syndrome. , 2011, , .		0
89	Chronic Lymphocytic Leukemia Shares a Common Cellular Origin with Regulatory B10 Cells. Blood, 2011, 118, 286-286.	0.6	0
90	Abstract 4178: Tcl1 enhances keratinocytesâ€™ survival/proliferation by promoting erk and jnk/sap phosphorylation at the expense of p38 and by controlling c-fos expression through miR-29b and miR-181a-1. , 2012, , .		0

#	Article	IF	Citations
91	Gistic Evaluation in Sezary Syndrome. Blood, 2012, 120, 4814-4814.	0.6	0
92	Abstract 3974: A preclinical study for miR181b as therapeutic in Eu-TCL1FL-tg mouse model for CLL. , 2015, , .		0
93	Abstract 936: Skin microenvironment enhances proliferation index and activates mTORC 1 signaling in sezary syndrome. , 2016, , .		0
94	TCL1. , 2017, , 4465-4469.		0
95	Abstract 761: The role of PI3 kinase pathway in the the skin of Sezary syndrome. , 2018, , .		0
96	The ACC melanoma pilot project: â€œReal-worldâ€•evaluation of an NGS platform for molecular characterization of melanoma in Italy.. Journal of Clinical Oncology, 2019, 37, e14600-e14600.	0.8	0